Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey

By sjmartinez • January 17, 2024

Lu Y, Liu Y, Jastreboff AM, Khera R, Ndumele CD, Rodriguez F, Watson KE, Krumholz HM. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010640. doi: 10.1161/CIRCOUTCOMES.123.010640. Epub 2023 Nov 11. Erratum in: Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e000126. PMID: 37950677; PMCID: PMC10782930.

Tags: adult, Cardiology/Epi, cardiovascular diseases, Ethnicity, Obesity, overweight, Publications

Bioelectronic block of stellate ganglia mitigates pacing-induced heterogeneous release of catecholamine and neuropeptide Y in the infarcted pig heart

Vrabec T, Bender S, Chan SA, Cha S, Haridas S, Hanna P, Ajijola OA, Shivkumar K, Smith C, Ardell JL. Bioelectronic block of stellate ganglia[...]

Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable

Tobis JM, Carroll JD. Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable? Circulation. 2024 Nov 19;150(21):1669-1670. doi: 10.1161/CIRCULATIONAHA.124.071851. Epub 2024 Nov 18.[...]

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Abdel Jawad M, Spertus JA, Ikeaba U, Greene SJ, Fonarow GC, Chiswell K, Chan PS. Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With[...]